AI Patents in Biotech and Chemistry: Domain-Specific Challenges
Why AI patent drafting for life sciences is fundamentally different - from chemical formulas to gene sequences to EPO requirements.
AI Patents in Biotech and Chemistry: Why Standard Tools Fail Here
Drafting a patent for a mechanical component is a text exercise. Drafting a patent for a novel antibody or a catalytic process is a multimodal challenge where chemical structures, sequence listings, biological data, and regulatory requirements converge. AI tools built for general patent work hit fundamental limits in life sciences. This article analyzes why - and what domain-specific solutions must do differently.
Why Biotech and Chemistry Patents Are Different
The differences start at the most fundamental level: language. While mechanical or software patents work primarily with natural language and occasional figures, chemistry and biotech patents are multimodal. They contain SMILES notation and Markush structures, amino acid and nucleotide sequences in standard format, experimental data in tabular form with statistical analyses, and reaction schemes with conditions, yields, and selectivities.
A general language model can learn patent claim formulation. But it cannot reliably validate a chemical structure in SMILES notation, check a protein sequence for plausibility, or assess the completeness of a working example against the EPO's enablement requirements. These capabilities require domain-specific training on specialist literature, patent databases, and sequence databases.
Structure-First AI Drafting: The Right Approach
Leading AI drafting tools for life sciences follow a "structure-first" approach. Instead of starting with a text prompt, the drafting process begins with the chemical or biological structure of the invention. The system analyzes the structure, identifies functionally relevant groups or domains, generates Markush structures with meaningful generalizations, and then formulates claims that capture the structure in patent-legally precise language.
The decisive advantage: the system "understands" the chemical or biological logic of the invention and can suggest generalizations that are chemically sound - not merely linguistically plausible. A standard LLM might formulate a claim that encompasses a chemical group that would be unstable or toxic in practice. A structure-based system catches such problems.
In practice, comparative studies from 2026 show that structure-based drafting tools deliver 35 to 45 percent higher first-draft quality for chemistry patents than general patent LLMs - measured by the number of corrections required by the patent attorney.
EPO Requirements for Biotech Patent Applications
The European Patent Office imposes specific requirements on biotech applications that go far beyond what applies to mechanical or software inventions. Rule 42(1)(f) EPC requires the indication of at least one way of carrying out the invention. For biotechnological inventions, this means in practice: detailed protocols that a person skilled in the art must be able to reproduce.
Sufficiency of disclosure (Art. 83 EPC) is the most frequent objection for biotech patents. The EPO requires that the description contains enough information to make the invention reproducible across the entire claimed scope. For an antibody patent, that means: the sequence alone is not enough. The skilled person must also be able to follow the expression conditions, purification steps, and characterization methods.
AI drafting tools for biotech must know these requirements and integrate them into the draft. A system that formulates an antibody claim without automatically checking the working examples for sufficiency generates applications that will fail during EPO examination.
Patentability of AI-Discovered Molecules
One of the most fascinating questions at the intersection of AI and life sciences is the patentability of molecules discovered or optimized by AI systems. The fundamental question: who is the inventor?
The EPO took a clear position in the DABUS decision (J 8/20): an AI system cannot be named as inventor. The inventor must be a natural person. In practice, this means: the scientist who conceived the AI system, selected the training data, and evaluated the results is the inventor - not the AI.
This has consequences for patent drafting practice. The description must clearly present the human inventor's contribution without concealing the role of AI. The EPO expects transparency about the use of AI tools but requires that the inventive contribution be attributable to a natural person.
Leading pharmaceutical companies including Insilico Medicine, Recursion Pharmaceuticals, and Exscientia have now filed hundreds of patent applications for AI-discovered molecules. Grant rates so far are in the range of conventional pharmaceutical patents - a sign that patent offices treat AI as a tool, not as an obstacle to patentability.
IP Strategies of Leading Pharma Companies
The pharmaceutical industry's IP strategy for AI-assisted discoveries has differentiated significantly in 2026. Three approaches can be identified.
The first approach protects the AI tool itself: algorithms, training pipelines, and specific architectures are filed as software patents. This requires careful presentation of "technical character" within the EPO framework - not a trivial task.
The second approach protects the outputs: molecules, formulations, or biomarkers discovered by AI are filed as classical composition-of-matter patents or use patents. Standard requirements for novelty, inventive step, and disclosure apply - but with the additional effort of transparently presenting the AI involvement.
The third approach combines both: a patent family covers both the AI tool and the results discovered with it. This creates a dense protection network but requires a coordinated filing strategy across multiple technology fields.
What AI Tools for Life Sciences Must Do Better
The requirements for AI patenting tools in life sciences can be summarized in five points. First: multimodal processing - the tool must natively handle chemical structures, sequences, and experimental data, not just text. Second: domain-specific validation - generated claims must be checked for chemical and biological plausibility. Third: rule-based compliance - the specific requirements of the EPO (and other offices) for biotech applications must be built in as a rule set. Fourth: sequence compliance - automatic verification of sequence formatting per WIPO Standard ST.26. Fifth: Markush optimization - intelligent generalization of chemical structures considering stability, toxicity, and prior art.
Conclusion
AI patent drafting for life sciences is a specialized discipline that demands specialized solutions. General patent LLMs can support the process but cannot replace the domain-specific expertise necessary for high-quality biotech and chemistry patents. The future belongs to structure-based, multimodal tools that understand the logic of chemistry and biology - not just the language of patent law.
WunderIP develops domain-specific AI modules for chemistry and biotech patents with structure-based drafting. Learn more about our life sciences solution.